Literature DB >> 25104740

Sterile keratitis after combined riboflavin-UVA corneal collagen cross-linking for keratoconus.

F C Lam1, P Georgoudis, P Geourgoudis1, M A Nanavaty1, S Khan1, D Lake1.   

Abstract

PURPOSE: To investigate patient risk factors and to look for potential causes of sterile infiltrates following an unexpected cluster of sterile keratitis after a routine collagen cross-linking (CXL) list.
METHODS: The records of all 148 cases of CXL were reviewed retrospectively. The equipment and solutions used and our clinic's standard operating procedure for CXL were reviewed. An in-vitro experiment to explore the variation in ultraviolet A (UVA) irradiance from fluctuations in the working distance of the UVA lamp was conducted.
RESULTS: The four patients who developed sterile infiltrates had steeper maximum corneal curvatures (68.0±7.3 D) and thinner pachymetry (389.9±49.0 μm) than the 144 who did not (57.0±8.2 D, P=0.05; 454.6±45.4 μm, P=0.08). A corneal curvature of >60 Dand a pachymetry of <425 μm were significant risk factors. All four affected cases obtained a complete resolution with topical antibiotics and steroids. The unaided VA and the maximum K improved from their pre-operative levels in three out of four patients. A 2-mm reduction in distance of the VEGA C.B.M. X-Linker from a treated surface increased irradiance to 3.5-3.7 mW/cm(2), which is above the threshold for endothelial toxicity.
CONCLUSION: Patients with thinner and steeper corneas are at an increased risk of developing sterile keratitis. The visual outcomes despite this complication are good.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25104740      PMCID: PMC4274277          DOI: 10.1038/eye.2014.173

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  22 in total

1.  Bacterial keratitis early after corneal crosslinking with riboflavin and ultraviolet-A.

Authors:  Matthias Pollhammer; Claus Cursiefen
Journal:  J Cataract Refract Surg       Date:  2009-03       Impact factor: 3.351

2.  A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results.

Authors:  Christine Wittig-Silva; Mark Whiting; Ecosse Lamoureux; Richard G Lindsay; Laurie J Sullivan; Grant R Snibson
Journal:  J Refract Surg       Date:  2008-09       Impact factor: 3.573

Review 3.  Keratoconus and related noninflammatory corneal thinning disorders.

Authors:  J H Krachmer; R S Feder; M W Belin
Journal:  Surv Ophthalmol       Date:  1984 Jan-Feb       Impact factor: 6.048

4.  Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study.

Authors:  Aldo Caporossi; Stefano Baiocchi; Cosimo Mazzotta; Claudio Traversi; Tomaso Caporossi
Journal:  J Cataract Refract Surg       Date:  2006-05       Impact factor: 3.351

Review 5.  Crosslinking treatment of progressive keratoconus: new hope.

Authors:  Gregor Wollensak
Journal:  Curr Opin Ophthalmol       Date:  2006-08       Impact factor: 3.761

6.  Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus.

Authors:  Gregor Wollensak; Eberhard Spoerl; Theo Seiler
Journal:  Am J Ophthalmol       Date:  2003-05       Impact factor: 5.258

7.  Stromal haze after combined riboflavin-UVA corneal collagen cross-linking in keratoconus: in vivo confocal microscopic evaluation.

Authors:  Cosimo Mazzotta; Angelo Balestrazzi; Stefano Baiocchi; Claudio Traversi; Aldo Caporossi
Journal:  Clin Exp Ophthalmol       Date:  2007-08       Impact factor: 4.207

8.  Corneal endothelial cytotoxicity of riboflavin/UVA treatment in vitro.

Authors:  Gregor Wollensak; Eberhard Spörl; Friedemann Reber; Lutz Pillunat; Richard Funk
Journal:  Ophthalmic Res       Date:  2003 Nov-Dec       Impact factor: 2.892

9.  Treatment of progressive keratoconus by riboflavin-UVA-induced cross-linking of corneal collagen: ultrastructural analysis by Heidelberg Retinal Tomograph II in vivo confocal microscopy in humans.

Authors:  Cosimo Mazzotta; Angelo Balestrazzi; Claudio Traversi; Stefano Baiocchi; Tomaso Caporossi; Cristina Tommasi; Aldo Caporossi
Journal:  Cornea       Date:  2007-05       Impact factor: 2.651

10.  Endothelial cell damage after riboflavin-ultraviolet-A treatment in the rabbit.

Authors:  Gregor Wollensak; Eberhard Spoerl; Michaela Wilsch; Theo Seiler
Journal:  J Cataract Refract Surg       Date:  2003-09       Impact factor: 3.351

View more
  6 in total

1.  Corneal crosslinking (CXL) with 18-mW/cm2 irradiance and 5.4-J/cm2 radiant exposure-early postoperative safety.

Authors:  Isaak Fischinger; Theo G Seiler; Karthiga Santhirasegaram; Moritz Pettenkofer; Chris P Lohmann; Daniel Zapp
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-04-17       Impact factor: 3.117

2.  Infectious keratitis after corneal crosslinking: systematic review.

Authors:  Caroline E Murchison; W Matthew Petroll; Danielle M Robertson
Journal:  J Cataract Refract Surg       Date:  2021-08-01       Impact factor: 3.528

3.  Transient anisocoria after corneal collagen cross-linking.

Authors:  George D Kymionis; Michael A Grentzelos; Nela Stojanovic; Theodore A Paraskevopoulos; Efstathios T Detorakis
Journal:  Case Rep Ophthalmol Med       Date:  2014-09-08

4.  Short-term changes in topometric indices after discontinuation of rigid gas permeable lens wear in keratoconic eyes.

Authors:  Preetam Kumar; Mohd Hasnat Ali; Jagadesh C Reddy; Pravin K Vaddavalli
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

5.  Retrospective Analysis of Sterile Corneal Infiltrates in Patients with Keratoconus after Cross-Linking Procedure.

Authors:  Magdalena Krok; Ewa Wróblewska-Czajka; Joanna Kokot; Anna Micińska; Edward Wylęgała; Dariusz Dobrowolski
Journal:  J Clin Med       Date:  2022-01-25       Impact factor: 4.241

6.  Safety and efficacy of repeated crosslinking assisted by transepithelial double-cycle iontophoresis in keratoconus progression after primary corneal crosslinking.

Authors:  Huping Wu; Lan Li; Shunrong Luo; Xie Fang; Xumin Shang; Zhiwen Xie; Xianwen Xiao; Huan He; Zhirong Lin; Zuguo Liu
Journal:  Eye (Lond)       Date:  2021-01-07       Impact factor: 4.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.